The CLL Tribune Q4 Reader Poll Results

March 25, 2016

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

December 2015-January 2016

During December 2015-January 2016, the CLL Society conducted a poll among readers of the second issue of The CLL Tribune. The survey included questions assessing participation and/or interest in clinical trials, types of treatment, if any, participation and/or interest in face-to-face support groups, as well as demographic information. 164 complete responses were received:

Average age – 66 (range 47-89)
20% Male, 80% Female
95% were patients; 5% were caregivers
99% of respondents expressed interested in participating in a face-to-face support group if one was available in their area

Twenty-seven percent of respondents are currently participating or have participated in one or more clinical trials in the past. Almost half would consider participating in a clinical trial in the future. Twenty percent have not yet received any treatment. [Figure 1]

Figure 1. Treatment Status

Thirty-four percent reported that they have been treated with chemotherapy or with chemo-immunotherapy, such as FCR, BR, FR, PCR; chlorambucil with or without R or others or; any of these using the antibodies, obinutuzumab or ofatumumab instead of rituximab. Forty-one percent have not received any treatment yet. [Figure 2] One-quarter of respondents report being treated outside of a clinical trial with a novel agent, such as ibrutinib (Imbruvica) or idelalisib (Zydelig).